Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists.
暂无分享,去创建一个
[1] C. Kilts,et al. Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens , 1986, Brain Research.
[2] S. Iversen,et al. Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones , 1983, Nature.
[3] J. Metzger,et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets , 1996, Neuropharmacology.
[4] C. Gregory. Comprehensive Textbook of Psychiatry/VI , 1996 .
[5] E. Fuchs,et al. Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal systems to stress, in the male rat , 1984, Neurochemistry International.
[6] R. Naylor,et al. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret , 1996, British journal of pharmacology.
[7] A. Benzer,et al. CSF of neuroleptic-naive first-episode schizophrenic patients: Levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin) , 1996, Biological Psychiatry.
[8] A. Siegel,et al. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat , 1993, Brain Research.
[9] S. File. Anxiolytic Action of a Neurokinin1 Receptor Antagonist in the Social Interaction Test , 1997, Pharmacology Biochemistry and Behavior.
[10] C. Maggi,et al. The substance P (NK1) receptor antagonist (±)-CP-96,345 causes sedation and motor impairment in Swiss albino mice in the black-and-white box behavioral paradigm , 1992, Neuroscience Letters.
[11] G. M. Halliday,et al. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus , 1991, Neuroscience.
[12] I. Hendry,et al. Noxious heating of the skin releases immunoreactive substance P in the substantia gelatinosa of the cat: A study with antibody microprobes , 1987, Brain Research.
[13] S. Iversen,et al. Antinociceptive activity of NK1 receptor antagonists: non‐specific effects of racemic RP67580 , 1993, British journal of pharmacology.
[14] M. Kris,et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. , 1997, Journal of the National Cancer Institute.
[15] M. Koch,et al. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats , 1994, Behavioural Brain Research.
[16] M. E. Goldberg,et al. The effect of imipramine and selected drugs on attack elicited by hypothalamic stimulation in the cat. , 1971, Neuropharmacology.
[17] J. Lowe,et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.
[18] M. C. Chang,et al. Fertilization of Denuded Rabbit Eggs in vitro by Sperm recovered from the Uterus or Vagina , 1971, Nature.
[19] M. Kris,et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. , 1999, The New England journal of medicine.
[20] J. Mendels,et al. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder , 1995, Biological Psychiatry.
[21] H. Takagi,et al. Substance P afferents have synaptic contacts with dopaminergic neurons in the ventral tegmental area of the rat , 1990, Neuroscience Letters.
[22] T. Hökfelt,et al. Experimental immunohistochemical studies on the localization and distribution of substance P in cat primary sensory neurons , 1975, Brain Research.
[23] R. Hagan,et al. Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345 , 1991, British journal of pharmacology.
[24] S. Silberman,et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Maccoss,et al. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. , 1997, European journal of pharmacology.
[26] T. O'donohue,et al. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system , 1984, Peptides.
[27] C. Maggi,et al. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles , 1998, Neuropeptides.
[28] M. P. Turpin,et al. Modulation of the rat mesolimbic dopamine pathway by neurokinins , 1992, Behavioural Brain Research.
[29] R. Hagan,et al. Behavioural and biochemical responses following activation of midbrain dopamine pathways by receptor selective neurokinin agonists , 1991, Neuropeptides.
[30] J. Nurnberger,et al. CSF substance P immunoreactivity in affective disorders , 1985, Biological Psychiatry.
[31] R. Hargreaves,et al. Enantioselective inhibition of ampomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994 , 1994, Neuropharmacology.
[32] Y. de Koninck,et al. Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[33] Kiyohisa Takahashi,et al. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat , 1996, Brain Research.
[34] M. Brandão,et al. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test , 1996, Physiology & Behavior.
[35] T. Unger,et al. Central tachykinins: mediators of defence reaction and stress reactions. , 1995, Canadian journal of physiology and pharmacology.
[36] J. Henry,et al. Effects of substance P on functionally identified units in cat spinal cord , 1976, Brain Research.
[37] C. Whitty,et al. Neurokinin receptor mRNA localization in human midbrain dopamine neurons , 1997, The Journal of comparative neurology.
[38] Y. Minabe,et al. The effect of the acute and chronic administration of CP 96,345, a selective neurokinin1 receptor antagonist, on midbrain dopamine neurons in the rat: A single unit, extracellular recording study , 1996, Synapse.
[39] G. Seabrook,et al. Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices. , 1995, European journal of pharmacology.
[40] R G Hill,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.
[41] J. Sawynok. Novel aspects of pain management : opioids and beyond , 1999 .
[42] E. Brodin,et al. Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions , 1994, Neuropeptides.
[43] D. Reis,et al. Immunocytochemical localization of catecholamine synthesizing enzymes and neuropeptides in area postrema and medial nucleus tractus solitarius of rat brain , 1981, The Journal of comparative neurology.
[44] S. Hunt,et al. Substance P receptors: Localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand , 1984, Brain Research.